Código QR (código de barras bidimensional)

A nano-cocktail of the PARP inhibitor talazoparib and CDK inhibitor dinaciclib for the treatment of triple negative breast cancer

Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as to expand PARPi therapy to...

Fuld beskrivelse

Na minha lista:
Principais autores: Paige Baldwin, Shicheng Yang, Adrienne Orriols, Sherrie Wang, Needa Brown, Srinivas Sridhar
Format: Artigo
Sprog:Inglês
Udgivet: BMC 2024-03-01
Serier:Cancer Nanotechnology
Fag:
Nano-cocktail
Talazoparib
Dinaciclib
PARP inhibitor
CDK inhibitor
Triple-negative breast cancer
Online adgang:https://doi.org/10.1186/s12645-023-00240-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker